Cipla

Summer 2021
Article

The Cost and Evolution of Quality at Cipla Ltd, 1935–2016

By: Muhammad H. Zaman and Tarun Khanna

This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details

Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India

Citation

Find at Harvard

April 2011 (Revised April 2015)
Case

Cipla 2011

By: Rohit Deshpande, Sandra J. Sucher and Laura Winig

Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details

Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry

Citation

Educators

Purchase

February 2007
Supplement

Patents & Patients, CIPLA - Video

By: Rohit Deshpande

Keywords: Patents; Health; Media

Citation

Purchase

February 2007 (Revised January 2013)
Teaching Note

Cipla (TN)

By: Rohit Deshpande and Aldo Sesia Jr.

Citation

Purchase

June 2003 (Revised May 2006)
Case

By: Rohit Deshpande and Laura Winig

The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details